Compare ASC & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASC | FTH |
|---|---|---|
| Founded | 2010 | N/A |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 751.7M | 835.7M |
| IPO Year | 2013 | 2021 |
| Metric | ASC | FTH |
|---|---|---|
| Price | $19.02 | $34.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 577.6K | 293.0K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.31 | $17.50 |
| 52 Week High | $20.03 | $42.14 |
| Indicator | ASC | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 62.69 | 50.77 |
| Support Level | $18.14 | $30.30 |
| Resistance Level | $18.91 | $36.63 |
| Average True Range (ATR) | 0.53 | 3.49 |
| MACD | 0.06 | -0.58 |
| Stochastic Oscillator | 79.07 | 29.44 |
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The company markets its services directly to its customers and commercial pool operators and charters its vessels to them through a combination of spot, commercial pooling, and time-charter arrangements. The majority of its revenue is generated from spot voyages, which typically last less than three months.
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.